[ Price : $8.95]
A self-described radical HHS policy now requires all new vaccines to be evaluated in placebo-controlled trials before theyre licen...[ Price : $8.95]
FDA extends by three months its review of a Cytokinetics NDA for aficamten for treating patients with obstructive hypertrophic car...[ Price : $8.95]
FDA approves a Satsuma Pharmaceuticals 505(b)(2) NDA for Atzumi (dihydroergotamine (DHE)) nasal powder for the acute treatment of ...[ Price : $8.95]
The FDA Office of Scientific Integrity publishes a scheduling order for Vandas request for a hearing on a proposed CDER order to d...[ Price : $8.95]
The Associated Press reports FDA is attempting to rehire some travel support, food scientist, and Freedom of Information Act staff...[ Price : $8.95]
FDA approves the Element Science PMA for its Jewel Patch wearable cardioverter defibrillator.[ Price : $8.95]
FDA approves Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement platform for patients with severe aortic stenos...[ Price : $8.95]
A Phase 3 trial funded by Novo Nordisk showed that its Ozempic/Wegovy outperformed placebo in patients with steatohepatitis and fi...